Steve Hahn describes how Harbinger Health is trying to catch the earliest signals of cancer, and how this information might be used.

Uli Stilz talks about the collaborating on science that might slow or reverse the progression of cardiometabolic diseases.

Niko Kley explains the concept of molecular glues, and how Orionis is also trying to design cytokines that are selectively activated.

March Biosciences’ CEO Sarah Hein on the infrastructure available in Houston for biotech startups, and the science behind her CD5 CAR-T.

Michael Torres describes his work in Texas, co-founding ReCode, helping entrepreneurs in Houston, and founding a next-gen ADC company.

Ann Tanabe describes the institutions, facilities, funding, and people that are coming together to make Houston a competitive biotech town.

Rachel Layman and Clinton Yam talk about recent ADCs, new ways of targeting the estrogen receptor, and next-gen ADCs.

Jeff Jones describes the science behind radiopharmaceuticals and how both new targets and better isotopes are making them more effective.

Funda Meric-Bernstam describes how ADCs have improved over recent years and lists some of her favorite targets and indications.

He describes how PARP inhibitors were initial successes and where the field is going now beyond PARP with new targets.

Tyler Van Buren discusses recent news from Acelyrin and Rocket Pharma, and comments on Moderna, BridgeBio, Iovance, and Allogene.

Ferdinandos Skoulidis describes improvements being made to G12C inhibitors and the theoretical potential for pan-RAS inhibitors.

Ferran Prat describes what advantages MD Anderson offers to drug developers running trials, what makes a good partner, and areas of science

Ross Barrett describes how the Cancer Focus Fund provides financing, advice, and help with getting into the clinic at MD Anderson.

Dr. Heymach discusses KRAS, refined TKI matching, antibody-drug conjugates, cell therapies, and cancer vaccines.

Leslie Williams explains how harnessing tRNA might be used for nonsense mutation diseases and for marking unwanted proteins for destruction.

Brian Gallagher describes what it is like raising venture funds in biotech today and also offers areas of science that he is focused on.

Rosana Kapeller explains how Rome is looking at areas of the genome that do not encode for traditional proteins as the basis of disease.

Mike Nally describes Generate's near term programs how he sees computational advances changing where the field is headed over the long term.

Brian Skorney discusses this week’s data from Neurocrine Biosciences and Crinetics, and comments on Amgen, Regeneron, and Arbutus.